{"clinical_study": {"@rank": "103", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 02, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04331054"}, "id_info": {"org_study_id": "P 200394", "secondary_id": "2020-001306-35", "nct_id": "NCT04331054"}, "brief_title": "Protective Role of Inhaled Steroids for Covid-19 Infection", "acronym": "INHASCO", "official_title": "Protective Role of Inhaled Steroids for Covid-19 Infection", "sponsors": {"lead_sponsor": {"agency": "Assistance Publique - H\u00f4pitaux de Paris", "agency_class": "Other"}}, "source": "Assistance Publique - H\u00f4pitaux de Paris", "oversight_info": {"has_dmc": "Yes", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "We hypothesize that inhaled steroid therapy and long acting beta 2 adrenergic agonist, widely\n      prescribed in asthma patients, may also have a local protective effect against coronavirus\n      infection, even in patients without asthma.\n\n      The primary purpose is To compare time to clinical improvement in patients receiving standard\n      of care associated to the combination budesonide/formoterol or standard of care only.\n\n      Time (in days) to clinical improvement is defined as the time from randomization to an\n      improvement of two points (from the status at randomization) on a seven-category ordinal\n      scale or live discharge from the hospital, whichever came first within 30 days."}, "detailed_description": {"textblock": "D1 inclusion / randomization visit:\n\n      Patients who meet the eligibility criteria and whose infection with Covid-19 has been\n      confirmed within 48 hours will be included in the respiratory diseases department by the\n      pneumologist investigator.\n\n      Patients will be randomized either to the control group or to the intervention group. For\n      interventional patients, trial treatment (SYMBICORT RAPIHALER 200/6 \u00b5) will begin within 12\n      hours.\n\n      Follow-up period (D2 to D29) and end of study visit (D30):\n\n      Throughout their hospital stay, patients will be followed in accordance with the practice of\n      the service.\n\n      During hospitalization, investigators are free to decide for antibiotics, steroids, anti\n      viral drugs, hydroxychloroquine and oxygen support management in accordance with local\n      practice. None of the laboratory tests are made for the study. They are usually performed in\n      patients hospitalized for acute respiratory infection.\n\n      Interventional patient will also be treated with SYMBICORT RAPIHALER 200/6 \u00b5g (2 puffs 2\n      times a day).\n\n      In the event that the patient is discharged from hospital before the end of his\n      participation, he will be contacted by phone on D30 in order to obtain information concerning\n      the period outside hospitalization"}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "April 2020"}, "completion_date": {"@type": "Anticipated", "#text": "July 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "July 2020"}, "phase": "Phase 3", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "None (Open Label)"}, "primary_outcome": {"measure": "Time (in days) to clinical improvement within 30 days after randomization", "time_frame": "within 30 days", "description": "Time (in days) to clinical improvement is defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first within 30 days.\nThe seven-category ordinal scale consisted of the following categories:\nNot hospitalized with resumption of normal activities\nNot hospitalized, but unable to resume normal activities\nHospitalized, not requiring supplemental oxygen\nHospitalized, requiring supplemental oxygen\nHospitalized, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both;\nHospitalized, requiring ECMO, invasive mechanical ventilation, or both\nDeath.\nThese parameters will be evaluated daily during hospitalization."}, "secondary_outcome": [{"measure": "Mortality rate at D30", "time_frame": "At day30"}, {"measure": "Time (in days) from randomization to death", "time_frame": "up to 30 days after randomization"}, {"measure": "Number of days alive outside ICU within 30 days", "time_frame": "At day30"}, {"measure": "Number of days alive free of invasive or non-invasive ventilation within 30 days", "time_frame": "At day30"}, {"measure": "Number of days alive with oxygen therapy within 30 days", "time_frame": "At day30"}, {"measure": "Maximal oxygen rate within 30 days", "time_frame": "At day30"}, {"measure": "Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)", "time_frame": "at Day 7"}, {"measure": "Number of days alive outside hospital within 30 days", "time_frame": "at Day 30"}, {"measure": "Use of antibiotics for respiratory (proved or suspected) infection within 30 days", "time_frame": "at Day 30"}, {"measure": "Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)", "time_frame": "at Day 7"}, {"measure": "Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.", "time_frame": "up to 30 days after randomization"}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "436"}, "condition": ["Covid-19 Infection", "Hospitalization in Respiratory Disease Department"], "arm_group": [{"arm_group_label": "1: Usual practice", "arm_group_type": "Active Comparator", "description": "arm will be follow during 30 days"}, {"arm_group_label": "2: Usual practice + SYMBICORT RAPIHALER", "arm_group_type": "Experimental", "description": "Usual practice + SYMBICORT RAPIHALER 200/6 \u00b5g ( 2 puffs bid during 30 days)"}], "intervention": [{"intervention_type": "Drug", "intervention_name": "2: Usual practice + SYMBICORT RAPIHALER", "description": "2 puffs bid during 30 days by inhalation", "arm_group_label": "2: Usual practice + SYMBICORT RAPIHALER"}, {"intervention_type": "Other", "intervention_name": "1: Usual practice", "description": "Usual practice", "arm_group_label": "1: Usual practice"}], "eligibility": {"criteria": {"textblock": "Inclusion criera :\n\n          -  Patient \u2265 18 years old and \u2264 75 years old\n\n          -  Laboratory proved infection by COVID-19 within 2 days\n\n          -  Hospitalization is required (based on investigator judgement)\n\n          -  Patient affiliated to a social security regime\n\n          -  Patient able to give free, informed and written consent\n\n        Exclusion criteria :\n\n          -  Oxygen flow rate >8l/min at inclusion\n\n          -  Current treatment with any inhaled steroid (any other form of steroid administration\n             does not exclude the patient)\n\n          -  Intensive care unit is required for the patient (based on investigator judgement)\n\n          -  Patient with cognitive impairment which do not guarantee proper use of the treatment\n             by the patient himself\n\n          -  Pregnant or breastfeeding women\n\n          -  Participation in another interventional drug study involving human participants and\n             concerning COVID-19 infection or being in the exclusion period of a previous study\n             involving human participants\n\n          -  Contraindications to the treatments (history of hypersensitivity)"}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No"}, "overall_official": {"last_name": "Camille TAILLE, MD, PhD", "role": "Principal Investigator", "affiliation": "Assistance Publique - H\u00f4pitaux de Paris"}, "overall_contact": {"last_name": "Camille TAILLE, MD, PhD", "phone": "+33 1 40 25 68 63", "email": "camille.taille@aphp.fr"}, "overall_contact_backup": {"last_name": "Bruno CRESTANI, MD, PhD", "phone": "+33 1 40 25 68 63", "email": "bruno.crestani@aphp.fr"}, "location": {"facility": {"name": "H\u00f4pital Bichat - Service de Pneumologie", "address": {"city": "Paris", "zip": "75010", "country": "France"}}, "contact": {"last_name": "Camille TAILLE, MD, PhD", "phone": "+33 1 40 25 68 63", "email": "camille.taille@aphp.fr"}}, "location_countries": {"country": "France"}, "verification_date": "March 2020", "study_first_submitted": "March 29, 2020", "study_first_submitted_qc": "April 1, 2020", "study_first_posted": {"@type": "Estimate", "#text": "April 2, 2020"}, "last_update_submitted": "April 1, 2020", "last_update_submitted_qc": "April 1, 2020", "last_update_posted": {"@type": "Estimate", "#text": "April 2, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "keyword": ["Covid-19", "Asthma", "Inhaled steroids", "Formoterol", "Oxygen"], "condition_browse": {"mesh_term": ["Infection", "Communicable Diseases", "Respiration Disorders", "Respiratory Tract Diseases"]}, "intervention_browse": {"mesh_term": "Budesonide, Formoterol Fumarate Drug Combination"}}}